Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00809276 · ClinicalTrials.gov registry record · Phase 1
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT00809276 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 92 participants.
The verdict
NCT00809276, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
Interventions
- DRUG Busulfan, Fludarabine, Cytoxan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00809276
The ClinicalTrials.gov registry entry for NCT00809276 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Busulfan, Fludarabine, Cytoxan is the first listed.
NCT00809276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00809276 about?
NCT00809276 is a clinical study titled "Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY". The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
What is the current status of trial NCT00809276?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2009-05. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00809276?
The interventions under investigation include: Busulfan, Fludarabine, Cytoxan (DRUG).
Who is sponsoring clinical trial NCT00809276?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.